Accelerate Multiple Sclerosis drug
Generally more than 15 years are needed to bring a new drug into the market. Patients need to shorten this time. All together we can speed the process by selectively funding critical phases of drug discovery pathway and the crowdfunding platform offers a perfect way to join our efforts in a common project. All the efforst are valuables. Today, our hope of turning a new treatment for people with multiple sclerosis into reality is open to all of you. We need to cover our fund objective as soon as possible. Our promising drug candidate AP-1 is waiting your help to start its way to clinical trials. Be a member of our team!
ANKAR PHARMA’s drug candidate aimed to multiple sclerosis is AP-1, a first-in-class small molecule with a dual innovative mechanism of action and high activity in preclinical models. AP-1 has shown high activity in all key components associated to MS in the worldwide accepted model of MS: the experimental allergic encephalitis (EAE) one. AP-1 is able to decrease the clinical symptoms (neurological score) in the EAE model after chronic preventive treatment or, in the worst situation, when the compound is administered at the peak of the disease. The efficacy in this murine model is similar or better that the produced by fingolimod, the most recent approved drug for MS orally treatment. Moreover, AP-1 is able to reduce inflammation, protects olygodendrocyte from death and promotes their gowth and it is able to increase remyelinization. AP-1 penetrates in the brain and can be orally administered.
Excellent news! The US Patent Office has just granted us the patent for our AP-1 drug. We already have the Spanish patent and we are expecting the European patent in few months!
Hace pocos meses hemos demostrado la eficacia preclinica de AP-1 en un modelo murino de retinosis pigmentaria (transgenico rd10). Hemos comprobado que en explantes de retina, AP-1 protege los fotorecptores. In vivo, por administracion i.p., sabemos que protege fotoreceptores, disminuye la activación de la microglia y consigue frenar la perdida de vision de los animales (mediante electroretinograma).
Después de meses de discusiones y matizaciones técnicas, la focina de patentes de EEUU ha aprobado la patente de nuestra molécula AP-1. Ya tenemos la patente española, la de EEUU y muy pronto la europea. Es una gran noticia que nos anima a seguir adelante.